Amgen, Allergan clear Phase III with Herceptin biosimilar

July 21, 2016 4:00 PM

21 0

Amgen, Allergan clear Phase III with Herceptin biosimilar

Amgen ($AMGN) has big biosimilar goals for this year. Fresh off a positive FDA panel earlier this month for what could be its first approved biosimilar for Humira (adalimumab), now the biotech and partner Allergan ($AGN) have reported positive top-line Phase III data for a Herceptin (trastuzumab) biosimilar to treat breast cancer.

It’s hoping for an FDA approval this year for the Humira biosimilar, which has a Sept. 25 FDA review date. And also plans to submit to the FDA for its Avastin (bevacizumab) biosimilar, for which it reported positive Phase III data last year.

Read more

To category page

Loading...